CN101029050A - Synthesis of 7-ethyl-N-camptothecin oxide - Google Patents
Synthesis of 7-ethyl-N-camptothecin oxide Download PDFInfo
- Publication number
- CN101029050A CN101029050A CN 200710017652 CN200710017652A CN101029050A CN 101029050 A CN101029050 A CN 101029050A CN 200710017652 CN200710017652 CN 200710017652 CN 200710017652 A CN200710017652 A CN 200710017652A CN 101029050 A CN101029050 A CN 101029050A
- Authority
- CN
- China
- Prior art keywords
- ethyl
- camptothecine
- oxidation
- camptothecin
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A process for synthesizing 7-ethyl-N-camptothecine oxide includes such steps as adding catalyst to glacial acetic acid solvent, adding H2O2, stirring, adding 7-ethyl camptothecine, reacting, vacuum concentrating, and recrystallizing in the mixture of chloroform and methanol.
Description
Technical field
The present invention relates to the synthetic method of a kind of 7-ethyl-N-oxidation camptothecine.
Background technology
Irinotecan is a kind of PTS, is mainly used in the treatment digestive system tumor clinically as cancer of the stomach, colorectal carcinoma, the rectum cancer etc., and curative effect is preferably arranged, and also can be used for treating leukemia, bladder cancer, liver cancer etc.The crucial actives of irinotecan is exactly intermediate 7-ethyl-N-oxidation camptothecine.Because of it is a kind of active alkaloid, synthetic middle meeting produces a large amount of by products, and synthetic difficulty is very big.If condition control is bad, reaction is incomplete, and its unreacted raw material is mixed in the product, is difficult to separate, but also can produces a large amount of by products, also is difficult to separate.
Present technology is earlier glacial acetic acid and hydrogen peroxide to be mixed; Be warming up to 80 ℃, add the 7-ethyl-camptothecin, oxidizing reaction 3h concentrates, and filters, and gets crude product.Particularly in the oxidizing reaction, must strict control reaction conditions, time, temperature is key factor, however the reaction times has lacked or temperature is low, all can make raw material reaction incomplete, and when the raw material unreacted is complete, just begin to produce by product.So be not enough only with period and temperature.
At present, a large amount of patent documentations both at home and abroad all are adjusting processes on time, temperature, proportioning raw materials, can not solve root problem.
Summary of the invention
The present invention proposes the synthetic method of a kind of 7-ethyl-N-oxidation camptothecine, it has solved, and the synthetic difficulty of existing synthetic method is big, synthesis condition is difficult to control, easily produce a large amount of by products, by product is difficult to isolating technical problem.
Technical solution of the present invention is:
The synthetic method of a kind of 7-ethyl-N-oxidation camptothecine may further comprise the steps:
1] adopt ordinary method to prepare intermediate 7-ethyl-camptothecin;
2] get catalyzer according to 0.1%～3% of 7-ethyl-camptothecin weight;
3] catalyzer is added in the Glacial acetic acid solvent, slowly add 30% hydrogen peroxide down in normal temperature again, stir 0.5h;
3] add intermediate 7-ethyl-camptothecin, temperature of reaction is no more than 60 ℃, and reaction times 1-2h is evaporated to driedly, and excess is with chloroform-methanol mixed solvent recrystallization, 7-ethyl-N-oxidation camptothecine.
Above-mentioned catalyzer can be heteropolyacid, and the weight percent of itself and 7-ethyl-camptothecin is 0.5%-2%.
Above-mentioned catalyzer also can be phospho-molybdic acid, and the weight percent of itself and 7-ethyl-camptothecin is 0.2%-1.5%.
Above-mentioned catalyzer also can be phospho-wolframic acid, and the weight percent of itself and 7-ethyl-camptothecin is 0.5%-3%.
Above-mentioned catalyzer also can be Vanadium Pentoxide in FLAKES, and the weight percent of itself and 7-ethyl-camptothecin is 0.2%-2%.
Above-mentioned catalyzer also can be ammonium molybdate, and the weight percent of itself and 7-ethyl-camptothecin is 0.2%-2%.
Above-mentioned reaction times the best is 1h, and temperature of reaction the best is 40--58 ℃.
The advantage of the inventive method is:
1, make synthesis temperature reduce to 50 ℃ by original 80 ℃.Synthetic method in the background technology is under the situation that does not add catalyzer, if synthesis temperature is lower than 60 ℃, then reaction is very slow, if synthesis temperature is higher than 60 ℃, can produce a large amount of by products again.The inventive method is added effective catalyst, solved fully low-temp reaction speed slowly and high temperature produce the problem of a large amount of by products, saved a large amount of energy, reduced environmental pollution.
2, make the reaction times reduce to 1.5h by original 3h.Synthetic method in the background technology is under the situation that does not add catalyzer, if when generated time is lower than 2h, then reactivity is very low; When if generated time is higher than 2h, has by product again and produce thereupon.The inventive method has been added effective catalyst, and raw material reaction not exclusively in short-term, long reaction time produces the problem of a large amount of by products again to have solved the reaction times fully.Both save the energy, improved quality product again.
3, the inventive method yield height.The yield of the synthetic method in the background technology is about 70%, and the inventive method adopts effective catalyst in oxidizing process, and yield can reach 85%.
4, no coupling product of the present invention produces.The by product that is produced in the synthetic method in the background technology does not have utility value, and is difficult to separate.The present invention adopts brand-new synthetic method, has utilized catalyzer, and no coupling product produces.
Embodiment
The invention provides the effective catalyst method of multiple synthetic 7-ethyl-N-oxidation camptothecine:
Embodiment 1:
0.05～0.2g heteropolyacid catalyst is added in the 1800mL Glacial acetic acid, slowly add 200mL30% hydrogen peroxide (oxygenizement) down in normal temperature again, stir 0.5h, add 10g intermediate 7-ethyl-camptothecin, be warming up to 40～58 ℃ of reaction 1h, be evaporated to dried, excess filters, in 60 ℃ of dry 4h with chloroform-methanol mixed solvent recrystallization, get yellow needle crystal, be 7-ethyl-N-oxidation camptothecine 9.1g, productive rate 85%mp255 ℃ (decomposition).NMR (DMSO-d6): 0.87 (3H, t, J=7Hz), 1.28 (3H, t, j=7Hz), 1.84 (2H, G, J=7Hz), 3.10 (3H, G, J=7Hz), 5.26 (2H, s), 5.36 (2H, s), 6.24 (1H, s, D
2D-is commutative), 7.80 (3H, m), 8.10 (1H, s), 8.35 (1H, m).MS:m/E[M
+] (C
22H
2ON
2O
5=392) .NMR and MS have confirmed that all product structure HPLC normalization method confirms that purity is 96%.Get product.
Embodiment 2:
The phospho-molybdic acid catalyzer of 0.01～0.15g is added in the 1800mL Glacial acetic acid, slowly add the 200mL30% hydrogen peroxide down in normal temperature again, stir 0.5h, add 10g intermediate 7-ethyl-camptothecin, be warming up to 40～58 ℃ of reaction 1h, be evaporated to dried, excess filters, in 60 ℃ of dry 4h with chloroform-methanol mixed solvent recrystallization, get yellow needle crystal, be 7-ethyl-N-oxidation camptothecine 9.19g, productive rate 86%.Mp255 ℃ (decomposition).NMR (DMSO-d6): 0.87 (3H, t, J=7HZ), 1.28 (3H, t, J=7HZ), 1.84 (2H, G, J=7HZ), 3.10 (3H, G, J=7HZ), 5.26 (2H, s),, 5.36 (2H, s), 6.24 (1H, s, D
2D-is commutative), 7.80 (3H, m), 8.10 (1H, s), 8.35 (1H, m) .MS:m/E[M
+] (C
22H
2ON
2O
5=392) .NMR and MS have confirmed that all product structure HPLC normalization method confirms that purity is 96%.Get product.
Embodiment 3:
The phosphotungstic acid catalyst of 0.05～0.3g is added in the 1800mL Glacial acetic acid, slowly add the 200mL30% hydrogen peroxide down in normal temperature again, stir 0.5h, add 10g intermediate 7-ethyl-camptothecin, be warming up to 40～58 ℃ of reaction 1h, be evaporated to dried, excess filters, in 60 ℃ of dry 4h with chloroform-methanol mixed solvent recrystallization, get yellow needle crystal, be 7-ethyl-N-oxidation camptothecine 9.1g, productive rate 85%mp255 ℃ (decomposition).NMR (DMSO-d6): 0.87 (3H, t, J=7HZ), 1.28 (3H, t, J=7HZ), 1.84 (2H, G, J=7Hz), 3.10 (3H, G, J=7HZ), 5.26 (2H, s), 5.36 (2H, s), 6.24 (1H, s, D
2D-is commutative), 7.80 (3H, m), 8.10 (1H, s), 8.35 (1H, m) .MS:m/E[M
+] (C
22H
2ON
2O
5=392) .NMR and MS have confirmed that all product structure HPLC normalization method confirms that purity is 96%.Get product.
Embodiment 4:
The vanadium pentoxide catalyst of 0.02～0.2g is added in the 1800mL Glacial acetic acid, slowly add the 200mL30% hydrogen peroxide down in normal temperature again, stir 0.5h, add 10g intermediate 7-ethyl-camptothecin, be warming up to 40～58 ℃ of reaction 1h, be evaporated to dried, excess filters, in 60 ℃ of dry 4h with chloroform-methanol mixed solvent recrystallization, get yellow needle crystal, be 7-ethyl-N-oxidation camptothecine 9.0g, productive rate 84%mp255 ℃ (decomposition).NMR (DMSO-d6): 0.87 (3H, t, J=7HZ), 1.28 (3H, t, J=7HZ), 1.84 (2H, G, J=7HZ), 3.10 (3H, G, J=7HZ), 5.26 (2H, s), 5.36 (2H, s), 6.24 (1H, s, D
2D-is commutative), 7.80 (3H, m), 8.10 (1H, s), 8.35 (1H, m) .MS:m/E[M
+] (C
22H
2ON
2O
5=392) .NMR and MS have confirmed that all product structure HPLC normalization method confirms that purity is 96%.Get product.
Embodiment 5:
The ammonium molybdate catalyzer of 0.02～0.2g is added in the 1800mL Glacial acetic acid, slowly add the 200mL30% hydrogen peroxide down in normal temperature again, stir 0.5h, add 10g intermediate 7-ethyl-camptothecin, be warming up to 40～58 ℃ of reaction 1h, be evaporated to dried, excess filters, in 60 ℃ of dry 4h with chloroform-methanol mixed solvent recrystallization, get yellow needle crystal, be 7-ethyl-N-oxidation camptothecine 9.0g, productive rate 84%mp255 ℃ (decomposition).NMR (DMSO-d6): 0.87 (3H, t, J=7HZ), 1.28 (3H, t, J=7HZ), 1.84 (2H, G, J=7HZ), 3.10 (3H, G, J=7HZ), 5.26 (2H, s), 5.36 (2H, s), 6.24 (1H, s, D
2D-is commutative), 7.80 (3H, m), 8.10 (1H, s), 8.35 (1H, m).MS:m/E[M
+] (C
22H
2ON
2O
5=392) .NMR and MS have confirmed that all product structure HPLC normalization method confirms that purity is 96%.Get product.
More than each embodiment through more than 6 times repeatedly the experiment, yield is all very stable.
The principle of the invention: at first utilize propionic aldehyde, ethylation reaction generates intermediate 7-ethyl-camptothecin.7-ethyl-the reaction mechanism of N-oxidation camptothecine is to use the Peracetic Acid oxidizing reaction in solvent acetic acid, but directly unsatisfactory with the Peracetic Acid reaction, and forms a large amount of by products.So the mechanism of this reaction constantly produces Peracetic Acid after can thinking that basically hydrogen peroxide adds in the glacial acetic acid, and simultaneous oxidation 7-ethyl-camptothecin.The 7-ethyl-camptothecin is progressively oxidation in the continuous formation of Peracetic Acid.So the time is less than 1.5h reaction not exclusively, can produce a large amount of by products again after being higher than 2h.For this reason, the present invention is by testing instruments, and high performance liquid phase is followed the tracks of detection.Confirm that temperature of reaction is lower than 60 ℃, reaction times 1.5h is an optimum reaction condition, but this condition must could realize under the condition of adding catalyzer.
The inventive method reaction process is as follows:
Claims (7)
1, the synthetic method of a kind of 7-ethyl-N-oxidation camptothecine is characterized in that: said method comprising the steps of:
1] adopt ordinary method to prepare intermediate 7-ethyl-camptothecin;
2] get catalyzer according to 0.1%～3% of 7-ethyl-camptothecin weight;
3] catalyzer is added in the Glacial acetic acid solvent, slowly add 30% hydrogen peroxide down in normal temperature again, stir 0.5h;
3] add intermediate 7-ethyl-camptothecin, temperature of reaction is no more than 60 ℃, and reaction times 1-2h is evaporated to driedly, and excess is with chloroform-methanol mixed solvent recrystallization, 7-ethyl-N-oxidation camptothecine.
2, the synthetic method of 7-ethyl according to claim 1-N-oxidation camptothecine, it is characterized in that: described catalyzer is a heteropolyacid, the weight percent of itself and 7-ethyl-camptothecin is 0.5%-2%.
3, the synthetic method of 7-ethyl according to claim 1-N-oxidation camptothecine, it is characterized in that: described catalyzer is a phospho-molybdic acid, its weight percent is 0.1%-1.5%.
4, the synthetic method of 7-ethyl according to claim 1-N-oxidation camptothecine, it is characterized in that: described catalyzer is a phospho-wolframic acid, its weight percent is 0.5%-3%.
5, the synthetic method of 7-ethyl according to claim 1-N-oxidation camptothecine, it is characterized in that: described catalyzer is a Vanadium Pentoxide in FLAKES, its weight percent is 0.2%-2%.
6, the synthetic method of 7-ethyl according to claim 1-N-oxidation camptothecine, it is characterized in that: described catalyzer is an ammonium molybdate, its weight percent is 0.2%-2%.
7, according to the synthetic method of the described 7-ethyl of arbitrary claim of claim 1 to 6-N-oxidation camptothecine, it is characterized in that: the described reaction times is 1h, and temperature of reaction is 40--58 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100176526A CN100558729C (en) | 2007-04-09 | 2007-04-09 | The synthetic method of a kind of 7-ethyl-N-oxidation camptothecine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100176526A CN100558729C (en) | 2007-04-09 | 2007-04-09 | The synthetic method of a kind of 7-ethyl-N-oxidation camptothecine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101029050A true CN101029050A (en) | 2007-09-05 |
| CN100558729C CN100558729C (en) | 2009-11-11 |
Family
ID=38714620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100176526A Expired - Fee Related CN100558729C (en) | 2007-04-09 | 2007-04-09 | The synthetic method of a kind of 7-ethyl-N-oxidation camptothecine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100558729C (en) |
-
2007
- 2007-04-09 CN CNB2007100176526A patent/CN100558729C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100558729C (en) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220204529A1 (en) | Method for preparing lornoxicam | |
| Ferro et al. | An improvement in the preparation of some carbohydrate benzylidene acetals | |
| CN101805327B (en) | Rabeprazole sodium compound and novel preparation method thereof | |
| CN113429376B (en) | Continuous synthesis method of epsilon-caprolactone | |
| WO2014202031A1 (en) | Method for co-production of adipic acid and nitrocyclohexane | |
| CN113214223B (en) | Preparation method of Voranolan fumarate impurity | |
| CN101070315B (en) | Method for preparing omeprazole | |
| CN101029050A (en) | Synthesis of 7-ethyl-N-camptothecin oxide | |
| CN111253457A (en) | Method for preparing 16 α -hydroxy prednisolone | |
| CN114749209B (en) | Preparation process of monobutyralte and magnetic solid catalyst | |
| DE2539435B2 (en) | PROCESS FOR PRODUCING NICOTIC AND ISONICOTIC AMIDE | |
| CN114478243A (en) | Method for synthesizing dihydroxy dimethyl terephthalate by oxygen catalytic oxidation method | |
| CN1830953A (en) | Process for preparing iminodiacetonitrile | |
| CN100340558C (en) | N,N-dipyridyl 3,4,9,10-tetraformyl diimine derirative and its synthesis method | |
| CN110128500B (en) | Ugi mixed solvent process for preparing alpha-amido amides | |
| CN104262415B (en) | D arabinose production methods | |
| CN115536603B (en) | Preparation method of organic intermediate | |
| CN1830956A (en) | Industrial prodn. method for producing sodium bisulfite methyl naphthoquinone | |
| CN105175355A (en) | Preparation method of 2-cyanophenothiazine | |
| CN117865882A (en) | Preparation method of 4-nitropyridine-N-oxide | |
| CN111675689B (en) | Chemical synthesis method of rosuvastatin intermediate | |
| CN112500312A (en) | Synthesis method of o-chlorobenzonitrile | |
| CN110407720B (en) | Synthetic method for preparing substituted guanidine by desulfurizing thiourea under catalysis of iodine | |
| CN117185997A (en) | Synthesis process of nicotinamide | |
| CN103864875A (en) | Selective oxidation method for hexa(hepta)decene-pregna-11-alpha-hydroxy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091111 Termination date: 20130409 |